NCT00093457 2023-08-04
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
9 trialsNCT00589420 2022-02-17
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00090545 2018-06-14
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00466752 2017-11-22
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
University of Washington
Phase 2 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00424385 2014-07-21
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Oncology Specialists, S.C.
Phase 1 Completed
NCT00414388 2014-04-07
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
Oncology Specialists, S.C.
Phase 1/2 Completed
NCT00619996 2009-02-26
P1
Italian Trial in Medical Oncology
Phase 2 Completed